Form 4: Sotera Health Executive Sells Over 126K Shares

Sentiment:

Insider Transaction Report 26 August 2025 6:08 PM

Sotera Health's President of Sterigenics, Michael P. Rutz, reported the sale of 126,611 shares of common stock for approximately $2.07 million, effective August 22, 2025.

Worse than expectedThe President of Sterigenics, a key executive, is selling a substantial number of shares. While this transaction is pre-planned under a 10b5-1 plan, insider selling can often be interpreted by the market as a negative signal regarding the company's near-term prospects or valuation.

Summary

Michael P. Rutz, President of Sterigenics at Sotera Health Co (SHC), reported a transaction involving the sale of common stock.
The transaction, scheduled for August 22, 2025, involves the disposition of 126,611 shares of common stock.
The shares were sold at an average weighted price of $16.3833, with prices ranging from $16.30 to $16.54 per share.
The total value of the shares sold is approximately $2,074,200.96.
Following this transaction, Mr. Rutz will beneficially own 450,204 securities, comprising 80,901 Restricted Stock Units (RSUs) and 369,303 shares of Common Stock.
The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the insider sale of a significant number of shares by a high-ranking executive. While such sales can be for personal financial planning, they are often viewed by the market as a potential lack of confidence or a signal that the executive believes the stock is adequately valued.

Positives

Negatives

The sale of a significant number of shares by a high-ranking executive, even if pre-planned, can be perceived negatively by the market as it might suggest a lack of confidence in the company's future prospects or a desire to diversify holdings.

Risks

Future Outlook

The filing indicates a future transaction date of August 22, 2025, for the sale of common stock. Additionally, it details future vesting schedules for various stock options and performance-based RSUs, with vesting commencing as late as March 3, 2026, and option expiration dates extending to March 4, 2034. These details outline the executive's future equity compensation and planned share dispositions.

Management Comments

The reporting person undertakes, upon request by the Commission staff, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Industry Context

Comparison to Industry Standards

Stakeholder Impact

Shareholders may interpret the executive's sale of shares as a negative signal, potentially impacting investor confidence and the company's stock price.
Employees holding company stock or options may monitor such insider transactions for insights into management's view of future performance.

Next Steps

The actual execution of the common stock sale on August 22, 2025.
Continued vesting of various stock options and performance-based RSUs according to their respective schedules, with the next vesting commencement for performance RSUs on March 3, 2026.

Key Dates

Date	Description
11/20/2020	Stock options granted under the 2020 Incentive Plan, vesting in four equal installments on each of the first four anniversaries of the grant date. Power of Attorney for Mr. Rutz filed as an exhibit to Form 3.
03/02/2022	Stock options granted under the 2020 Incentive Plan, vesting in three equal installments on each of the first three anniversaries of the grant date.
03/06/2023	Stock options granted under the 2020 Incentive Plan, vesting annually in three equal installments commencing March 2, 2024.
03/02/2024	Commencement of annual vesting for stock options granted on March 6, 2023.
03/04/2024	Stock options granted under the 2020 Incentive Plan, vesting annually in three equal installments commencing March 2, 2025.
03/02/2025	Commencement of annual vesting for stock options granted on March 4, 2024.
03/03/2025	Performance-based RSUs granted under the 2020 Incentive Plan.
08/22/2025	Date of the reported common stock sale by Michael P. Rutz.
08/26/2025	Signature date of the Form 4 filing.
03/03/2026	Commencement of annual vesting for performance-based RSUs granted on March 3, 2025, in 60%, 20%, and 20% installments.
11/20/2030	Expiration date for stock options granted on November 20, 2020.
03/02/2032	Expiration date for stock options granted on March 2, 2022.
03/06/2033	Expiration date for stock options granted on March 6, 2023.
03/04/2034	Expiration date for stock options granted on March 4, 2024.

Recommendation

hold

The sale of shares by a key executive, while a negative signal, is a single event and could be due to personal financial planning or diversification, especially given it's a pre-planned 10b5-1 transaction. Without further context on company performance, broader insider activity, or specific market catalysts, a 'hold' recommendation is prudent, advising investors to monitor future developments and company fundamentals rather than reacting solely to this single insider sale.

Keywords

Sotera Health, SHC, Insider Trading, Stock Sale, Executive Compensation, Form 4, Sterigenics

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.